SCHEMBL4209779

SCHEMBL4209779

COc1ccc(CNC(=O)c2cc(-c3ccc(OC)cc3)sc2NC(N)=O)cc1

nearest known ligand 0.77

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 17/20 0.77
IKBKB O14920 2/20 0.58
MAP4K4 O95819 1/20 0.56
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4215417 0.95 CHEK1 (0.70) CHEK1IKBKBMAP4K4MAPT
SCHEMBL4208133 0.93 CHEK1 (0.67) CHEK1IKBKBMAP4K4
SCHEMBL4206749 0.92 CHEK1 (0.65) CHEK1IKBKBMAP4K4
SCHEMBL4216732 0.88 CHEK1 (0.60) CHEK1MAPT
SCHEMBL4206514 0.87 CHEK1 (0.60) CHEK1MAP4K4
SCHEMBL3612027 0.87 CHEK1 (1.00) CHEK1IKBKB
SCHEMBL4221790 0.87 CHEK1 (0.71) CHEK1IKBKBMAP4K4
SCHEMBL4218805 0.87 CHEK1 (0.73) CHEK1IKBKBMAP4K4
SCHEMBL4224511 0.86 CHEK1 (0.63) CHEK1IKBKBMAP4K4MAPT
SCHEMBL4223830 0.86 CHEK1 (0.63) CHEK1IKBKBMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054396-A1 SUBSTITUTED THIOPHENES AND USES THEREOF ASTRAZENECA AB (SE) 2009-02-26 US claimed
JP-2007502308-A 2007-02-08 JP claimed
US-20060281666-A1 Substitute thiophenes and uses therof ASTRAZENECA AB (SE) 2006-12-14 US claimed
CN-1867557-A Substitute thiophenes and uses therof ASTRAZENECA AB (SE) 2006-11-22 CN claimed
EP-1660474-A1 SUBSTITUTED THIOPHENES AND USES THEREOF AstraZeneca AB (SE) 2006-05-31 EP claimed
WO-2005016909-A1 SUBSTITUTED THIOPHENES AND USES THEREOF ASTRAZENECA AB (SE) 2005-02-24 WO claimed
US-20090054396-A1 SUBSTITUTED THIOPHENES AND USES THEREOF ASTRAZENECA AB (SE) 2009-02-26 US disclosed
US-20090054396-A1 SUBSTITUTED THIOPHENES AND USES THEREOF ASTRAZENECA AB (SE) 2009-02-26 US disclosed
EP-1660474-B1 SUBSTITUTED THIOPHENES AND USES THEREOF ASTRAZENECA AB (SE) 2008-10-29 EP disclosed
US-7423061-B2 Substitute thiophenes and uses thereof ASTRAZENECA AB (SE) 2008-09-09 US disclosed
US-7423061-B2 Substitute thiophenes and uses thereof ASTRAZENECA AB (SE) 2008-09-09 US disclosed
US-7423061-B2 Substitute thiophenes and uses thereof ASTRAZENECA AB (SE) 2008-09-09 US disclosed
US-20060281666-A1 Substitute thiophenes and uses therof ASTRAZENECA AB (SE) 2006-12-14 US disclosed
CN-1867557-A Substitute thiophenes and uses therof ASTRAZENECA AB (SE) 2006-11-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054396-A1 SUBSTITUTED THIOPHENES AND USES THEREOF TPMT, ABCG2, TYMP CHEK1 297/4885IKBKB 1574/4885MAP4K4 3173/4885
US-20060281666-A1 Substitute thiophenes and uses therof TYMP, TPMT, MGMT CHEK1 602/4885IKBKB 3734/4885MAP4K4 4690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.